T. Rowe Price Associates’s Protara Therapeutics TARA Stock Holding History

T. Rowe Price Associates’s Portfolio TARA Stock Details TARA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$190K	Buy	36,306 +15,570	+75%	+$92.2K	﹤0.01%	2859
2025 Q4	$111K	Buy	20,736 +4,383	+27%	+$24.4K	﹤0.01%	2932
2025 Q3	$72K	Hold	16,353	–	–	﹤0.01%	2976
2025 Q2	$50K	Buy	+16,353	New	+$56.4K	﹤0.01%	3008
2021 Q2	–	Sell	-319,326	Closed	-$5.03M	–	2953
2021 Q1	$5.03M	Sell	319,326 -114,272	-26%	-$2.12M	﹤0.01%	1466
2020 Q4	$10.5M	Sell	433,598 -14,495	-3%	-$312K	﹤0.01%	1343
2020 Q3	$7.54M	Buy	+448,093	New	+$10.4M	﹤0.01%	1354

Other funds holding TARA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

T. Rowe Price Associates's TARA Position: Q1 2026 in Review

T. Rowe Price Associates increased its Protara Therapeutics (TARA) stake by 75% in Q1 2026, buying an estimated $92.2K and bringing the position to 36,306 shares worth $190K. The position accounts for ﹤0.01% of the portfolio, ranked #2859.

T. Rowe Price Associates first reported a position in TARA in Q3 2020 and has held it in 7 quarters since. The position peaked at $10.5M in Q4 2020. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

T. Rowe Price Associates held 36,306 shares of Protara Therapeutics worth $190K as of Q1 2026.
T. Rowe Price Associates bought 15,570 Protara Therapeutics shares in Q1 2026, an estimated $92.2K.
Protara Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2859 holding.
T. Rowe Price Associates first reported a position in Protara Therapeutics in Q3 2020 and has held it in 7 quarters since.
T. Rowe Price Associates's Protara Therapeutics position peaked at $10.5M in Q4 2020.
114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.